Navigation Links
Harrisvaccines Awarded Vaccine Product Licensure
Date:9/20/2012

AMES, Iowa, Sept. 20, 2012 /PRNewswire/ -- Harrisvaccines announces United States Department of Agriculture (USDA) licensure of the company's swine flu vaccine, approved by the Department's Center for Veterinary Biologics (CVB) for disease caused by swine influenza virus (SIV) H3N2.

The vaccine is the first to be licensed by the USDA CVB that utilizes RNA Particle Technology. Dr. Kurt Kamrud, Vice President of Research and Chief Scientific Officer at Harrisvaccines, led the company's development and application of RNA Particle Technology - with the ultimate goal of producing a swine influenza vaccine that could be manufactured faster and safer than those produced using modified live or inactivated/killed virus technologies.

This groundbreaking platform allows for the manufacture of vaccines without ever isolating a live virus from infected animals. Only a gene from an infected animal is required to prepare vaccines in as little as four weeks.  The vaccine, licensed as Swine Influenza Vaccine, RNA, Product Code 19A5.D0, was initially submitted to USDA CVB for licensing in 2009.

"When we submitted our license application in 2009, the USDA didn't have an established category into which the product fit," said Jodi French, USDA Liaison at Harrisvaccines.  "There were additional regulatory hoops to jump through in order to achieve this first license."

In addition to USDA licensure of the vaccine, Harrisvaccines received a United States Veterinary Biologics Establishment License, #592, which approves the Ames-based facility for future manufacture of new vaccines for a broader spectrum of veterinary applications, from swine and cattle to companion animal and farmed aquaculture. 

"We were founded in 2006, so this has been a long, challenging road to licensure for a novel technology to be used in animal health," Harrisvaccines founder and President Dr. D.L. "Hank" Harris said. "These USDA licenses mark a major milestone, and perhaps most importantly, signal that this technology is a key fixture in our country's continuing fight against biological threats and ever-changing pathogens."

"With USDA licensure of both the SIV H3N2 vaccine and our Ames manufacturing facility, we expect additional licenses for vaccines manufactured using RNA Particle Technology to be issued on more condensed timelines. With new strains of this virus identified as recently as July of this year, we're particularly interested in our potential to manufacture custom, farm-specific vaccines in a matter of weeks instead of months," Harris said.

About Harrisvaccines

Headquartered in Ames, Iowa, Harrisvaccines focuses on improving animal health and enhancing productivity in the swine, cattle, equine and farmed shrimp industries. Harrisvaccines employs two unique RNA platforms to develop custom farm-specific vaccine products against animal diseases. For more information, visit www.harrisvaccines.com.


'/>"/>
SOURCE Harrisvaccines
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Healionics Awarded $900k Grant from NIH
2. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
3. Managed Health Care Associates, Inc. (MHA) Awarded Commonwealth of Massachusetts GPO Contract
4. Sequent Medical, Inc. Awarded U.S. Patent for MicroBraid Technology
5. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
6. ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
7. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
8. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
9. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
10. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen ... http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... , ... May 05, 2016 , ... Dr. Benjamin Stong ... non-surgical hair loss treatment. Dr. Stong is double board certified and the only ... for the treatment of hair loss. Non-surgical therapies such as stem cells can be ...
(Date:5/5/2016)... ... , ... Talent Tech Labs (TTL) is pleased to announce its ... Nurses Week (May 6-12). Currently, HireNurses is a job listing and matching platform ... Tech Lab Virtual Incubation program, they will dramatically expand the functionality and ease of ...
(Date:5/5/2016)... ... 05, 2016 , ... VisualDx announced today its ... is the first point of care diagnostic support system to be widely used, ... speeds diagnosis, therapy decisions and patient education for emergency physicians, hospitalists and primary ...
(Date:5/5/2016)... ... May 05, 2016 , ... ACLS Certification ... announce its new referral program, giving participants incentive for spreading the word about ... and we know many professionals share resources with their friends and colleagues,” said ...
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD ... Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was titled ... the conference about her unique specialization in treating Lipedema. Dr. Byrd is considered one ...
Breaking Medicine News(10 mins):